Cargando…
Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis
BACKGROUND: Methylation of the tumor suppressor gene H-cadherin (CDH13) has been reported in many cancers. However, the clinical effect of the CDH13 methylation status of patients with bladder cancer remains to be clarified. METHODS: A systematic literature search was performed to identify eligible...
Autores principales: | Chen, Feng, Huang, Tao, Ren, Yu, Wei, Junjun, Lou, Zhongguan, Wang, Xue, Fan, Xiaoxiao, Chen, Yirun, Weng, Guobin, Yao, Xuping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004266/ https://www.ncbi.nlm.nih.gov/pubmed/27578166 http://dx.doi.org/10.1186/s12894-016-0171-5 |
Ejemplares similares
-
Association of VDR gene TaqI polymorphism with the susceptibility to prostate cancer in Asian population evaluated by an updated systematic meta-analysis
por: Chen, Liangliang, et al.
Publicado: (2018) -
Association of rs3787016 in Long Non-coding RNAs POLR2E and rs2910164 in MiRNA-146a with Prostate Cancer: A Systematic Review and Meta-analysis
por: HUANG, Shuaishuai, et al.
Publicado: (2018) -
Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
por: Pu, Weilin, et al.
Publicado: (2016) -
Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer
por: Lin, Ying-Li, et al.
Publicado: (2014) -
Prognostic significance of CDH13 hypermethylation and mRNA in NSCLC
por: Xue, Ruilin, et al.
Publicado: (2014)